imatinib


Also found in: Dictionary, Wikipedia.

imatinib

 [ĭ-mă´tĭ-nib″]
an inhibitor acting specifically on an abnormal enzyme form that is created by the Philadelphia chromosome abnormality and present in chronic myeloid leukemia. It is used in the treatment of chronic myeloid leukemia during blast crisis, accelerated phase, or chronic phase after failure of interferon-α therapy, administered orally as the mesylate salt.

im·a·tin·ib

(im-ă-tin'ib),
An oral agent important in the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors; a specific inhibitor of the Philadelphia reciprocal chromosome translocation-created protein tyrosine kinase enzyme, which works by blocking rapid growth of the mutant clone of tumor cells.

imatinib

(ĭ-măt′ə-nĭb)
n.
A tyrosine kinase inhibitor, C29H31N7O, used in its mesylate form to treat certain types of leukemia and various other diseases.
References in periodicals archive ?
The public procurement includes the delivery of imatinib to treat patients with gist with a predicted amount of up to 720,000 mg.
Furthermore, HOTAIR inhibition results in higher sensitivity to imatinib by regulating MRP expression (15).
Pharmaceutical company Breckenridge Pharmaceutical Inc reported on Monday the receipt of the final approval from the US Food and Drug Administration for its Abbreviated New Drug Application for Imatinib Mesylate Tablets in 100mg and 400mg product strengths.
Briefly, 10 [micro]L/well of 50, 100, 150, and 200 [micro]M concentrations of apigenin, luteolin, 5-desmethyl sinensetin, and (as positive control) imatinib (5, 10, 25, 50 [micro]M) were added, and cells (90 [micro]L/well; [10.sup.5] cells/mL culture medium) were subsequently seeded and incubated for 72 h.
(5,14,15) Research by Chikkodi et al, in 124 newly diagnosed of CML chronic phase patients that received imatinib, 82.3% patient reached EMR, low-intermediate Hasford score had a higher prediction to reach EMR (p=0,0179).
All the enrolled patients were placed on Imatinib therapy (400 mg/day) and RT-PCR for BCR ABL1 transcript was repeated after three months.
Dusetzina, Ph.D., from Vanderbilt University in Nashville, Tenn., discuss potential barriers to effective generic price competition for specialty prescription drugs using the case of generic imatinib. Outpatient pharmacy claims were selected for May 1, 2001, to Sept.
Therefore, imatinib, an inhibitor of KIT that is a platelet-derived growth factor-a (PDGFR-a), came into use as the standard first-line agent for metastatic GIST [1],[2] and sunitinib is used for patients who are imatinib refractory.[8] Radiotherapy is not recommended as a treatment modality in the current treatment guidelines [1] and is only used with palliative intent for bone metastases.[2] This approach is based on previous reports that suggest that radiotherapy is not beneficial in the treatment of GIST [9] while it is considered a radiotherapy-resistant or minimally responsive entity.[10],[11],[12],[13] However, the results from a few case reports [14] and some retrospective data [15] reported that GIST is not uniformly radioresistant and may benefit from radiotherapy.[16]
In this retrospective study, we focus on several potential factors, such as clinicopathological parameters and imatinib treatment, to predict disease-free survival (DFS) and overall survival (OS) of 62 patients with DGISTs.
Therefore, we conducted a meta-analysis to elucidate which GIST genotype is the most sensitive to sunitinib following imatinib resistance.
Imatinib is a tyrosine kinase inhibitor that is used in various hematologic malignancies, including idiopathic hypereosinophilic syndrome (IHES) which is a myeloproliferative disorder characterized by sustained, nonreactive, unexplained persistent hypereosinophilia that commonly results in multiorgan dysfunction.